Dermatology News and Research

Latest Dermatology News and Research

CPS supports NACI recommendations for new shingles vaccine

The Canadian Pain Society (CPS) supports the National Advisory Committee on Immunization (NACI) recommendations for the use of a vaccine to significantly reduce the risk of developing herpes zoster (shingles) and post herpetic neuralgia in adults over the age of 60 without contraindications.

3 Feb 2010

Merz Pharma Group granted early termination in connection with BioForm Medical share tender offer

Merz Pharma Group today announced that it has been granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, by the U.S. Federal Trade Commission and the U.S. Department of Justice in connection with the previously announced US$5.45 per share cash tender offer made by Merz GmbH & Co. KGaA (“Merz”) and its acquisition subsidiary to purchase all outstanding shares of common stock of BioForm Medical, Inc..

3 Feb 2010

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients.

3 Feb 2010

FDA approves INNOPHARMA's ibutilide fumarate injection ANDA

INNOPHARMA LLC announced today FDA approval of the Abbreviated New Drug Application (ANDA) for ibutilide fumarate injection (the generic equivalent of Corvert® from Pfizer Inc).

2 Feb 2010

Positive results from Phosphagenics' TPM Phase 1B clinical study for transdermal delivery of oxycodone

Phosphagenics Limited today announced positive results from a Phase 1B clinical study using the Company’s patented TPM™ (Targeted Penetration Matrix) for the transdermal delivery of oxycodone. The results of the successful trial demonstrate that daily application of a TPM™ patch delivers therapeutic levels of oxycodone into the blood stream in a reproducible, consistent and sustained manner.

2 Feb 2010

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."

2 Feb 2010

Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint

LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.

2 Feb 2010

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis (nail and nail bed fungal infections).

1 Feb 2010

Oculus Innovative Sciences introduces Microcyn Solution for treatment of post-surgical wounds

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today unveiled Microcyn Solution with preservatives, at the New York Podiatric Clinical Conference & Exhibition being held in downtown Manhattan, January 29-31.

28 Jan 2010

Onset Therapeutics expands its sales force to create nationwide presence

Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company’s recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas.

28 Jan 2010

Depression raises risks of advanced and severe complications from diabetes

Depression raises risks of advanced and severe complications from diabetes, according to a prospective study of Group Health primary-care patients in western Washington. These complications include kidney failure or blindness, the result of small vessel damage, as well as major vessel problems leading to heart attack or stroke.

28 Jan 2010

Indoor tanning: FTC prohibits ITA from making false health and safety claims

The American Academy of Dermatology (Academy) applauds the Federal Trade Commission (FTC) for issuing a consent order that prohibits the Indoor Tanning Association (ITA) from making false health and safety claims about indoor tanning. The Academy raised its concerns about the false statements being made by the ITA with the FTC in 2008 after the ITA launched an advertising campaign designed to portray indoor tanning as safe and beneficial.

28 Jan 2010

Santica Research Labs launches CelluScience Anti-Cellulite Beaute Intensive dietary supplement

More than 85% of women in the U.S. have cellulite. Now, there is a revolutionary new anti-cellulite dietary supplement clinically proven to help target the thighs, hips and gluteal area.

28 Jan 2010

Warner Chilcott receives complete response letter from FDA for low dose oral contraceptive

Warner Chilcott plc announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) to its New Drug Application submitted in March 2009 for its "low dose" oral contraceptive (also referred to as WC 3016).

27 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

National Science Foundation awards grant to study biological mechanism of living cells

Learning how living cells can detect and respond to electric fields is the aim of a $570,000, three-year grant from the National Science Foundation to Min Zhao, professor of dermatology and ophthalmology at the UC Davis Health System and Center for Neuroscience.

27 Jan 2010

Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010

Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.

27 Jan 2010

LTW Technologies' LED LIGHTWAVE therapy device receives 5 FDA clearances

LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.

25 Jan 2010

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

25 Jan 2010

Dermatological nuisance caused by toilet seats making a comeback in pediatricians' offices

Considered a dermatological nuisance that was long gone, skin irritations caused by toilet seats appear to be making a comeback in pediatricians' offices, according to research led by Johns Hopkins Children's Center investigator Bernard Cohen, M.D.

25 Jan 2010

Dermatology News and Research

Latest Dermatology News and Research

CPS supports NACI recommendations for new shingles vaccine

Merz Pharma Group granted early termination in connection with BioForm Medical share tender offer

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

FDA approves INNOPHARMA's ibutilide fumarate injection ANDA

Positive results from Phosphagenics' TPM Phase 1B clinical study for transdermal delivery of oxycodone

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

Oculus Innovative Sciences introduces Microcyn Solution for treatment of post-surgical wounds

Onset Therapeutics expands its sales force to create nationwide presence

Depression raises risks of advanced and severe complications from diabetes

Indoor tanning: FTC prohibits ITA from making false health and safety claims

Santica Research Labs launches CelluScience Anti-Cellulite Beaute Intensive dietary supplement

Warner Chilcott receives complete response letter from FDA for low dose oral contraceptive

Abbott declares quarterly dividend of 40 cents per share

National Science Foundation awards grant to study biological mechanism of living cells

Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010

LTW Technologies' LED LIGHTWAVE therapy device receives 5 FDA clearances

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Dermatological nuisance caused by toilet seats making a comeback in pediatricians' offices

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Dermatology News and Research

Latest Dermatology News and Research

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in